-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD) is the main cause of neurodegenerative dementia worldwide
.
Early symptoms include short-term memory loss, decreased executive function, difficulty finding words, and visuospatial dysfunction
Alzheimer's disease (AD) is the main cause of neurodegenerative dementia worldwide
Preclinical studies in transgenic AD mouse models have found that the use of antiepileptic drugs to inhibit epileptiform activities is associated with improved behavior and histopathological signs of high excitability in the chronic network of the hippocampus
Recently, researchers have evaluated the ability of levetiracetam to improve the cognitive function of AD patients in an attempt to explore whether patients with Alzheimer's disease and epileptiform activity respond to levetiracetam treatment more than those without this nerve Patients with signs of network hypersynchronization are better
The Levetiracetam study of Alzheimer's disease-related network hyperexcitability (LEV-AD) is a phase 2a randomized double-blind placebo-controlled crossover clinical trial, from October 16, 2014 to July 2020 It took place on the 21st at the University of California, San Francisco and the University of Minnesota Twin Cities.
A total of 34 adult AD patients participated
.
Participants were adults 80 years of age and younger, with a simple mental status check score of 18 points or higher, and/or a clinical dementia score below 2 points
The Levetiracetam study of Alzheimer's disease-related network hyperexcitability (LEV-AD) is a phase 2a randomized double-blind placebo-controlled crossover clinical trial, from October 16, 2014 to July 2020 It took place on the 21st at the University of California, San Francisco and the University of Minnesota Twin Cities.
Group A took placebo twice a day for 4 weeks, and then took Levetiracetam 125 mg twice a day for 4 weeks
The main result is the ability of levetiracetam treatment to improve executive function (measured by the National Institutes of Health: Measures and Tools for Neurobehavioral Evaluation and Research [NIH-Examiner] Comprehensive Score)
- Of the 54 adults who underwent eligibility assessment, 11 did not meet the research criteria, and 9 refused to participate
.
A total of 34 adult AD patients (21 women (61.
In this randomized clinical trial, levetiracetam was well tolerated.
Literature source: https://jamanetwork-com.
washington.
80599.
net/journals/jamaneurology/fullarticle/2784539 https://jamanetwork-com.
washington.
80599.
net/journals/jamaneurology/fullarticle/2784539 Leave a message here
